Key Performance
More- Earnings Score: N/A
- Momentum Score: 26
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced the pricing of a $1.5 million follow-on offering of 2,477,292 units at $0.6055 per unit. The company plans to use net proceeds for preclinical and clinical development of HCW9302 and general corporate purposes. Additionally, HCW Biologics negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, subject to shareholder approval.
02/17/2026, 9:50 PM • GlobeNewswire
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
HCW Biologics showcased its lead product candidate HCW11-040, a multi-functional fusion protein combining pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, which demonstrates potential to expand exhausted T cells without side effects in cancer treatment.
10/22/2025, 9:00 AM • GlobeNewswire
HCW Biologics announced the selection of HCW11-040, a multi-functional fusion protein, as its lead product candidate for treating solid tumors. The immunotherapeutic combines pembrolizumab with specific cytokines and shows promising preclinical results in expanding T-cell responses without triggering cytokine storm.
09/16/2025, 8:00 AM • GlobeNewswire
HCW Biologics announced successful development of second-generation T-cell engagers targeting solid tumors, particularly pancreatic cancer and glioblastoma, with promising preclinical safety results in non-human primates and potential for treating multiple cancer types.
09/09/2025, 8:00 AM • GlobeNewswire
HCW Biologics has developed a novel pembrolizumab-based immune checkpoint inhibitor targeting solid tumors, particularly pancreatic and ovarian cancer, using its proprietary TRBC technology platform. The new immunotherapeutic shows potential to improve cancer treatment by simultaneously activating immune cells and promoting their tumor infiltration.
08/25/2025, 8:00 AM • GlobeNewswire
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported Q2 2025 financial results, highlighting a $5 million equity offering, ongoing clinical development of HCW9302 for alopecia areata, and strategic business development efforts including license agreement negotiations and T-cell engager research.
08/18/2025, 2:44 PM • GlobeNewswire
Hcw Biologics Revenue Plunges 98 Percent
HCW Biologics reported a significant revenue decline to $6,550 in Q2 2025, primarily due to a suspended licensing agreement. Despite narrowing its net loss to $1.9 million, the company faces ongoing financial challenges and continues to develop immunotherapies targeting inflammatory and autoimmune diseases.
08/14/2025, 6:33 PM • The Motley Fool
